rts logo

Is Biocryst Pharmaceuticals Inc. (BCRX) a good stock to buy now?

Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) is -11.19% lower on its value in year-to-date trading and has touched a low of $4.03 and a high of $8.96 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BCRX stock was last observed hovering at around $5.34 in the last trading session, with the day’s loss setting it -0.02%.

Currently trading at $5.32, the stock is 15.97% and 8.65% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.5 million and changing -0.37% at the moment leaves the stock -9.83% off its SMA200. BCRX registered -38.35% loss for a year compared to 6-month loss of -2.74%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The stock witnessed a 4.31% gain in the last 1 month and extending the period to 3 months gives it a -9.06%, and is 19.55% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.59% over the week and 6.73% over the month.

Biocryst Pharmaceuticals Inc. (BCRX) has around 536 employees, a market worth around $1.10B and $355.39M in sales. Profit margin for the company is -58.69%. Distance from 52-week low is 32.01% and -40.62% from its 52-week high. The company has generated returns on investments over the last 12 months (-59.94%).

with sales reaching $98.32M over the same period. The EPS is expected to grow by 47.50% this year, but quarterly earnings will post 21.20% year-over-year. Quarterly sales are estimated to grow 19.20% in year-over-year returns.

Biocryst Pharmaceuticals Inc. (BCRX) Top Institutional Holders

The shares outstanding are 205.77M, and float is at 198.78M with Short Float at 16.92%.

Biocryst Pharmaceuticals Inc. (BCRX) Insider Activity

The most recent transaction is an insider sale by SANDERS MACHELLE,the company’sDirector. SEC filings show that SANDERS MACHELLE sold 4,000 shares of the company’s common stock on Jun 15 ’23 at a price of $7.98 per share for a total of $31920.0. Following the sale, the insider now owns 25611.0 shares.

Biocryst Pharmaceuticals Inc. disclosed in a document filed with the SEC on Jun 14 ’23 that Hutson Nancy J (Director) sold a total of 12,866 shares of the company’s common stock. The trade occurred on Jun 14 ’23 and was made at $8.04 per share for $0.1 million. Following the transaction, the insider now directly holds 81818.0 shares of the BCRX stock.

Related Posts